Literature DB >> 32020030

Selective deletion of MyD88 signaling in α-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation.

Shuai Zhao1,2, Dina Dejanovic1,2, Peng Yao3, Shardul Bhilocha1, Tammy Sadler4, Anja Schirbel2, Gail West1, Genevieve Doyon1, Rocio Lopez5, Ren Mao1,6, Satya Kurada1, Sara El Ouali2, Guntram Grassl7, Paul L Fox3, Michael Cruise8, Daniel L Worthley9, Carol de la Motte1,2, Claudio Fiocchi1,2, Florian Rieder10,11.   

Abstract

Intestinal fibrosis leading to strictures remains a significant clinical problem in inflammatory bowel diseases (IBD). The role of bacterial components in activating intestinal mesenchymal cells and driving fibrogenesis is largely unexplored. Tamoxifen-inducible α-SMA promoter Cre mice crossed with floxed MyD88 mice were subjected to chronic dextran sodium sulfate colitis. MyD88 was deleted prior to or after induction of colitis. Human intestinal myofibroblasts (HIMF) were exposed to various bacterial components and assessed for fibronectin (FN) and collagen I (Col1) production. RNA sequencing was performed. Post-transcriptional regulation was assessed by polysome profiling assay. Selective deletion of MyD88 in α-SMA-positive cells prior to, but not after induction of, experimental colitis decreased the degree of intestinal fibrosis. HIMF selectively responded to flagellin with enhanced FN or Col1 protein production in a MyD88-dependent manner. RNA sequencing suggested minimal transcriptional changes induced by flagellin in HIMF. Polysome profiling revealed higher proportions of FN and Col1 mRNA in the actively translated fractions of flagellin exposed HIMF, which was mediated by eIF2 alpha and 4EBP1. In conclusion, selectivity of flagellin-induced ECM secretion in HIMF is post-transcriptionally regulated. The results may represent a novel and targetable link between the gut microbiota and intestinal fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32020030      PMCID: PMC7316631          DOI: 10.1038/s41385-020-0259-9

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  52 in total

Review 1.  Pattern recognition receptors and inflammation.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 3.  Toll-like receptors.

Authors:  Eva Marie Y Moresco; Diantha LaVine; Bruce Beutler
Journal:  Curr Biol       Date:  2011-07-12       Impact factor: 10.834

Review 4.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

5.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

6.  Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts.

Authors:  J P Burke; M F Cunningham; R W G Watson; N G Docherty; J C Coffey; P R O'Connell
Journal:  Br J Surg       Date:  2010-07       Impact factor: 6.939

7.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

Authors:  William S Mow; Eric A Vasiliauskas; Ying-Chao Lin; Phillip R Fleshner; Konstantinos A Papadakis; Kent D Taylor; Carol J Landers; Maria T Abreu-Martin; Jerome I Rotter; Huiying Yang; Stephan R Targan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 8.  Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem.

Authors:  Ilyssa O Gordon; Neha Agrawal; John R Goldblum; Claudio Fiocchi; Florian Rieder
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325

9.  Intestinal myofibroblasts in innate immune responses of the intestine.

Authors:  Jan-Michel Otte; Ian M Rosenberg; Daniel K Podolsky
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

10.  Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.

Authors:  Noam Jacob; Jonathan P Jacobs; Kotaro Kumagai; Connie W Y Ha; Yoshitake Kanazawa; Venu Lagishetty; Katherine Altmayer; Ariel M Hamill; Aimee Von Arx; R Balfour Sartor; Suzanne Devkota; Jonathan Braun; Kathrin S Michelsen; Stephan R Targan; David Q Shih
Journal:  Mucosal Immunol       Date:  2018-07-09       Impact factor: 7.313

View more
  17 in total

1.  Upregulation of miRNA-1228-3p alleviates TGF-β-induced fibrosis in renal tubular epithelial cells.

Authors:  Huajuan Shen; Qiang He; Yongze Dong; Lina Shao; Yueming Liu; Jianguang Gong
Journal:  Histol Histopathol       Date:  2020-07-28       Impact factor: 2.303

Review 2.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

3.  Mouse Models of Intestinal Fibrosis.

Authors:  Jiannan Li; Dina Dejanovic; Megan T Zangara; Jyotsna Chandra; Christine McDonald; Florian Rieder
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Fibroblasts as immune regulators in infection, inflammation and cancer.

Authors:  Sarah Davidson; Mark Coles; Tom Thomas; George Kollias; Burkhard Ludewig; Shannon Turley; Michael Brenner; Christopher D Buckley
Journal:  Nat Rev Immunol       Date:  2021-04-28       Impact factor: 53.106

5.  Association of Baseline Luminal Narrowing With Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease.

Authors:  Allison D Ta; Nicholas J Ollberding; Rebekah Karns; Yael Haberman; Adina L Alazraki; David Hercules; Robert Baldassano; James Markowitz; Melvin B Heyman; Sandra Kim; Barbara Kirschner; Jason M Shapiro; Joshua Noe; Maria Oliva-Hemker; Anthony Otley; Marian Pfefferkorn; Richard Kellermayer; Scott Snapper; Shervin Rabizadeh; Ramnik Xavier; Marla Dubinsky; Jeffrey Hyams; Subra Kugathasan; Anil G Jegga; Jonathan R Dillman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

Review 6.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

Review 7.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

Review 8.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

Review 9.  Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.

Authors:  Long-Yuan Zhou; Si-Nan Lin; Florian Rieder; Min-Hu Chen; Sheng-Hong Zhang; Ren Mao
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

Review 10.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.